Page 50 - Read Online

release cytarabine (DepoCyt) to intrathecal methotrexate in patients fluid concentration of gefitinib and erlotinib in patients with non-small
with neoplastic meningitis from solid tumors. Clin Cancer Res cell lung cancer. Cancer Chemother Pharmacol 2012;70:399-405.
1999;5:3394-402. 86. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong
72. Roth P, Wick W, Weller M. Steroids in neurooncology: actions, EK, Lee JS. Gefitinib as a first-line therapy of advanced or metastatic
indications, side-effects. Curr Opin Neurol 2010;23:597-602. adenocarcinoma of the lung in never-smokers. Clin Cancer Res
73. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire 2005;11:3032-7.
WL. Human breast cancer: correlation of relapse and survival with 87. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS.
amplification of the HER-2/neu oncogene. Science 1987;235:177-82. Epidermal growth factor receptor tyrosine kinase inhibitors as a
74. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, first-line therapy for never-smokers with adenocarcinoma of the lung
Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini having asymptomatic synchronous brain metastasis. Lung Cancer
E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. 2009;65:351-4.
Identifying breast cancer patients at risk for Central Nervous System 88. Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ,
(CNS) metastases in trials of the International Breast Cancer Study Costa DB, Rabin MS, Jackman DM, Johnson BE. The impact of
Group (IBCSG). Ann Oncol 2006;17:935-44. initial gefitinib or erlotinib versus chemotherapy on central nervous
75. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, system progression in advanced non-small cell lung cancer with
Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley EGFR mutations. Clin Cancer Res 2012;18:4406-14.
AM. Incidence of cerebral metastases in patients treated with 89. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK,
trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-43. Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J,
76. Pierga JY, Bidard FC, Cropet C, Tresca P, Dalenc F, Romieu G, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase
Campone M, Mahier Ait-Oukhatar C, Le Rhun E, Goncalves II trial of erlotinib plus concurrent whole-brain radiation therapy for
A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero JM, patients with brain metastases from non-small-cell lung cancer. J
Labbe-Devilliers C, Bachelot T. Circulating tumor cells and brain Clin Oncol 2013;31:895-902.
metastasis outcome in patients with HER2-positive breast cancer: the 90. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De
LANDSCAPE trial. Ann Oncol 2013;24:2999-3004. Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M,
77. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely
Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. N Engl J Med
Blackwell K. Trastuzumab emtansine for HER2-positive advanced 2013;368:2385-94.
breast cancer. N Engl J Med 2012;367:1783-91. 91. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T,
78. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner
Miles D, Samant M, Welslau M, Dieras V. Trastuzumab emtansine KD, Tursi J, Blackhall F. First-line crizotinib versus chemotherapy in
(T-DM1) versus lapatinib plus capecitabine in patients with HER2- ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
positive metastatic breast cancer and central nervous system 92. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S,
metastases: a retrospective, exploratory analysis in EMILIA. Ann Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno
Oncol 2015;26:113-9. S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.
79. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada Identification of the transforming EML4-ALK fusion gene in non-
A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, small-cell lung cancer. Nature 2007;448:561-6.
Vermette J, Zacharchuk C, Badwe R. Neratinib, an irreversible ErbB 93. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner
receptor tyrosine kinase inhibitor, in patients with advanced ErbB2- KD. CSF concentration of the anaplastic lymphoma kinase inhibitor
positive breast cancer. J Clin Oncol 2010;28:1301-7. crizotinib. J Clin Oncol 2011;29:e443-5.
80. Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. 94. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou
Exp Hematol Oncol 2015;4:33. C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire
81. Wang TJ, Saad S, Qureshi YH, Jani A, Nanda T, Yaeh AM, Rozenblat R, Camidge DR, Crino L. Clinical Experience With Crizotinib in
T, Sisti MB, Bruce JN, McKhann GM, Lesser J, Halmos B, Stoopler Patients With Advanced ALK-Rearranged Non-Small-Cell Lung
MB, Lassman AB, Cheng SK, Isaacson SR. Does lung cancer Cancer and Brain Metastases. J Clin Oncol 2015;33:1881-8.
mutation status and targeted therapy predict for outcomes and local 95. Falk AT, Poudenx M, Otto J, Ghalloussi H, Barrière J.
control in the setting of brain metastases treated with radiation? Adenocarcinoma of the lung with miliary brain and pulmonary
Neuro Oncol 2015;17:1022-8. metastases with echinoderm microtubule-associated protein like
82. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, 4-anaplastic lymphoma kinase translocation treated with crizotinib:
Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, a case report. Lung Cancer 2012;78:282-4.
Varmus H. EGF receptor gene mutations are common in lung cancers 96. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman
from “never smokers” and are associated with sensitivity of tumors to JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.
gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. Inhibition of mutated, activated BRAF in metastatic melanoma. N
83. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa Engl J Med 2010;363:809-19.
DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, 97. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin
Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht
EL, Lynch TJ, Iafrate AJ. Clinical features and outcome of patients JD. Vemurafenib in patients with BRAF(V600) mutation-positive
with non-small-cell lung cancer who harbor EML4-ALK. J Clin melanoma with symptomatic brain metastases: final results of an
Oncol 2009;27:4247-53. open-label pilot study. Eur J Cancer 2014;50:611-21.
84. Varella-Garcia M, Berry LD, Su PF, Franklin WA, Iafrate AJ, 98. Kim DW, Barcena E, Mehta UN, Rohlfs ML, Kumar AJ, Penas-
Ladanyi M, Camidge DR, Garon EB, Haura EB, Horn L, Khuri FR, Prado M, Kim KB. Prolonged survival of a patient with metastatic
Pao W, Rudin CM, Shaw AT, Schiller JH, Kris MG, Johnson BE, leptomeningeal melanoma treated with BRAF inhibition-based
Minna JD, Kwiatkowski DJ, Bunn PA. J Clin Oncol 2012;30, No therapy: a case report. BMC cancer 2015;15:400.
15_suppl:7589. 99. Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar
85. Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, S, Reyes C, Guerin A, Yim YM. Treatment patterns and outcomes
Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M. Cerebrospinal in BRAF V600E-mutant melanoma patients with brain metastases

174
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ May 20, 2016 ¦